Rob Coleman

3.3k total citations · 1 hit paper
48 papers, 2.3k citations indexed

About

Rob Coleman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Rob Coleman has authored 48 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Rob Coleman's work include Bone health and treatments (20 papers), Radiopharmaceutical Chemistry and Applications (11 papers) and Cancer Treatment and Pharmacology (8 papers). Rob Coleman is often cited by papers focused on Bone health and treatments (20 papers), Radiopharmaceutical Chemistry and Applications (11 papers) and Cancer Treatment and Pharmacology (8 papers). Rob Coleman collaborates with scholars based in United Kingdom, Belgium and United States. Rob Coleman's co-authors include Ingunn Holen, Penelope D. Ottewell, H. Kim Lyerly, Gamal Akabani, Michael A. Morse, René Rizzoli, Philippe Clézardin, Nicolas C. Buchs, Patrick Garnero and Jamal Zekri and has published in prestigious journals such as Journal of Clinical Oncology, Physiological Reviews and JNCI Journal of the National Cancer Institute.

In The Last Decade

Rob Coleman

47 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bone metastasis: mechanisms, therapies, and biomarkers

2020 243 citations Philippe Clézardin, Rob Coleman et al. profile →

Peers

Countries citing papers authored by Rob Coleman

Since Specialization

Citations

This map shows the geographic impact of Rob Coleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob Coleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob Coleman more than expected).

Fields of papers citing papers by Rob Coleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rob Coleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob Coleman. The network helps show where Rob Coleman may publish in the future.

Co-authorship network of co-authors of Rob Coleman

This figure shows the co-authorship network connecting the top 25 collaborators of Rob Coleman. A scholar is included among the top collaborators of Rob Coleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rob Coleman. Rob Coleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters 2023 ·Vaccines ·(unknown), (unknown), (unknown), (unknown), (unknown), Radha Krishan Shandil, (unknown), Gudepalya Renukaiah Rudramurthy, (unknown), (unknown), Rob Coleman, (unknown), Rajeev Dhere, (unknown)	9
2	A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results 2022 ·Journal of bone oncology ·Matthew Winter, Rob Coleman, (unknown), Carlo Palmieri, Chris Twelves, Sacha J. Howell, Iain R. Macpherson, Caroline Wilson, (unknown), Jacqui Gath, Christine L. Taylor, Richard Eastell, (unknown), Sarah Brown, Emma Rathbone, Janet E. Brown	9
3	CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial 2020 ·Trials ·Rob Coleman, Janet E. Brown, Emma Rathbone, Louise Flanagan, (unknown), (unknown), Sacha J. Howell, Chris Twelves, Carlo Palmieri, Anjana Anand, Iain R. Macpherson, Sarah Brown	11
4	Abstract GS1-06: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study 2018 ·Cancer Research ·Wolfgang Janni, Thomas W. P. Friedl, Tanja Fehm, Volkmar Müller, W. Lichtenegger, Jens‐Uwe Blohmer, Ralf Lorenz, Helmut Forstbauer, (unknown), (unknown), Inga Bekes, (unknown), Andreas Schneeweiß, Hans Tesch, Sven Mahner, (unknown), G. Heinrich, MW Beckmann, Rob Coleman, Brigitte Rack	9
5	Bone health in the elderly cancer patient: A SIOG position paper 2016 ·Cancer Treatment Reviews ·Jean‐Jacques Body, Evangelos Terpos, Bertrand Tombal, Peyman Hadji, Ahmed A. Arif, Annie Young, Matti Aapro, Rob Coleman	33
6	The Role of Computed Tomography Scanning of the Thorax in the Initial Assessment of Gestational Trophoblastic Neoplasia 2015 ·International Journal of Gynecological Cancer ·James Price, Christine Lo, (unknown), Matthew Winter, Rob Coleman, John Tidy, Barry W. Hancock	10
7	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial 2014 ·The Lancet Oncology ·Ivana Šestak, Shalini Singh, Jack Cuzick, Glen M. Blake, Rajesh Patel, Fatma Gossiel, Rob Coleman, Mitch Dowsett, John Forbes, Anthony Howell, Richard Eastell	53
8	The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome 2013 ·Journal of Obstetrics and Gynaecology ·Philip Savage, Ailsa Sita-Lumsden, (unknown), (unknown), Jan Everard, Rob Coleman, Rosemary A. Fisher, D Short, (unknown), (unknown), Michael J. Seckl	81
9	Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial 2012 ·Journal of bone oncology ·J. Lester, David Dodwell, Janet E. Brown, O.P. Purohit, Sandra A. Gutcher, (unknown), (unknown), Janet Horsman, Rob Coleman	15
10	Follow-up care for cancer survivors: the views of clinicians 2009 ·British Journal of Cancer ·(unknown), David Greenfield, Kate Absolom, Christine Eiser, Stephen J. Walters, Gisela Michel, Barry W. Hancock, John A. Snowden, Rob Coleman	55
11	Impact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasia 2009 ·Gynecologic Oncology ·(unknown), Rob Coleman, Jan Everard, John Tidy, Janet Horsman, (unknown), Barry W. Hancock	26
12	OC11. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II) 2008 ·Cancer Treatment Reviews ·Shalini Singh, Jack Cuzick, (unknown), Glen M. Blake, J G Truscott, Rob Coleman, (unknown), Anthony Howell	19
13	International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients 2007 ·European Journal of Cancer ·Jean-Jacques Body, Rob Coleman, Philippe Clézardin, Carla Ripamonti, René Rizzoli, Matti Aapro	55
14	Questioning specialists’ attitudes to breast cancer follow-up in primary care 2007 ·Annals of Oncology ·(unknown), Louise Hiller, Sarah Bathers, S. Bowden, Rob Coleman	49
15	Gestational Trophoblastic Disease: A Study of Mode of Evacuation and Subsequent Need for Treatment with Chemotherapy 2000 ·Gynecologic Oncology ·John Tidy, Alan Gillespie, Nicholas J. Bright, C. Radstone, Rob Coleman, B. W. Hancock	74
16	Markers of bone turnover for the management of patients with bone metastases from prostate cancer 2000 ·British Journal of Cancer ·Patrick Garnero, Nicolas C. Buchs, Jamal Zekri, René Rizzoli, Rob Coleman, Pierre D. Delmas	191
17	Migration of human dendritic cells after injection in patients with metastatic malignancies. 1999 ·PubMed ·Michael A. Morse, Rob Coleman, Gamal Akabani, (unknown), (unknown), H. Kim Lyerly	298
18	The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers 1999 ·European Journal of Cancer ·John F. R. Robertson, Wolfram Jaeger, (unknown), C. Selby, Rob Coleman, Anthony Howell, (unknown), (unknown), Emilio Bombardieri, J R C Sainsbury, Henrik Grönberg, E. Kumpulainen, R.W. Blamey	71
19	Glucocorticoids in cancer therapy 1992 ·Biotherapy ·Rob Coleman	41
20	The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases 1991 ·Calcified Tissue International ·Peter T. Daley‐Yates, David Dodwell, (unknown), Rob Coleman, Anthony Howell	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact